Dare Bioscience Inc (NASDAQ: DARE) is flying in the market this morning with gains that are better described in multiples than percentages. The gains come after the company announced the publication of clinical findings
The findings proved to be positive, leading to excitement among investors who are pushing the stock for the top. Today, we’ll talk about:
- The clinical findings;
- what we’re seeing from DARE stock as a result; and
- what we’ll be watching for ahead.
DARE Stock Gains On Clinical Findings
As mentioned above, Dare Bioscience is having a great start to the trading session this morning after announcing the publication of clinical findings. The announcement came via press release about an hour ago.
In the release, the company said that the publication of clinical findings for vaginally-administered tamoxifen has been published in a leading journal. The data was published in Clinical and Experimental Obstetrics and Gynecology, a leading international journal for publication of research focuesd on the development of therapies in obstetrics and gynecology.
In the release, DARE said that its candidate, DARE-VVA1, incorporates tamoxifen in a proprietary formulation. This formulationw as designed for vaginal delivery. Moreover, the company said that it holds the exclusive worldwide rights to patents issued in the U.S. and Japan that cover the use and delivery of DARE-VVA1 for vulvar and vaginal atrophy (VVA).
The company also holds a U.S. patent covering composition, use and delivery of DARE-VVA1 for VVA.
In the release, the company said that the publication was titled, “Weekly vaginal administration of tamoxifen for three months in post-menopausal women with vulvar and vaginal atrophy: a possible new treatment approach?”
In the publication, it was reported that a self-administered vaginal suppository containing tamoxifen, dosed daily for one week and followed by twice weekly for three months, showed significant improvements in reducing vaginal pH. DARE said that the publication showed that the treatment also led to reduce vaginal dryness without significant systemic absorption of tamoxifen.
What we’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Dare Bioscience, the news proved to be overwhelmingly positive.
After all, the publication further validated the company’s work in the development of DARE-VVA1, and with strong patent protection, the asset’s value is only going up. So, it’s not surprising to see that excited investors are pushing the stock for the top.
As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:47), DARE stock is trading at $3.05 per share after a gain of $2.15 per share or 238.89% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on DARE. In particular, we’re interested in following the story surrounding the company’s continued work to bring DARE-VVA1 to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!